Mirvetuximab soravtansine shows 16.4-month OS in ovarian cancer, though poor ECOG status and toxicity significantly impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results